Assoc. Prof. Dr. Shi-liang Huang | Tumor | Best Researcher Award

Sun Yat-sen University | China

AUTHOR PROFILE

Scopus

ORCID ID

๐Ÿง‘โ€๐Ÿ”ฌ DR. SHI-LIANG HUANG

Associate Professor in Medicinal Chemistry
Sun Yat-sen University, People’s Republic of China

๐ŸŽฏ OBJECTIVE

Dedicated Associate Professor specializing in Medicinal Chemistry, with a passion for driving innovation in drug discovery and development, focusing on the tumor microenvironment and the heat shock response.

๐Ÿ“˜ EARLY ACADEMIC PURSUITS

Dr. Huang’s academic journey began with a solid foundation in Chemistry and Biochemistry, laying the groundwork for a distinguished career. After excelling in undergraduate studies, Dr. Huang pursued advanced degrees in Medicinal Chemistry, demonstrating exceptional aptitude for research and innovation.

Key achievements during this phase include:

  • Masterโ€™s Thesis: Groundbreaking work on natural product derivatives for therapeutic applications.
  • Doctoral Research: Advanced studies on the mechanisms of small molecules in altering biochemical pathways.

๐Ÿข PROFESSIONAL ENDEAVORS

As an Associate Professor at Sun Yat-sen University, Dr. Huang has significantly contributed to the university’s reputation as a leading institution in medicinal research. His professional journey is marked by:

  • Leading Interdisciplinary Teams: Collaborating with experts in oncology, biochemistry, and computational modeling.
  • Research Innovation: Pioneering techniques in synthesizing inhibitors targeting heat shock proteins (HSPs) and heat shock factor 1 (HSF1).
  • Teaching Excellence: Mentoring students in natural medicinal chemistry and drug design methodologies.

๐Ÿงช CONTRIBUTIONS AND RESEARCH FOCUS

Dr. Huang’s work revolves around integrating bioorganic chemistry with tumor microenvironment studies to innovate cancer therapies. Key contributions include:

  • Medicinal Chemistry: Developing novel molecules with high specificity for cancer-related targets.
  • Natural Product Exploration: Isolating and modifying natural compounds to enhance their therapeutic potential.
  • Heat Shock Response Modulation: Designing inhibitors to disrupt HSF1 and HSP pathways, which are critical in cancer cell survival under stress.
  • Tumor Microenvironment Studies: Investigating how microenvironmental factors influence drug efficacy.

๐ŸŒŸ IMPACT AND INFLUENCE

Dr. Huang’s research has had a profound impact on the scientific community and beyond:

  • Published Works: Author of numerous peer-reviewed articles in high-impact journals.
  • Citations and Recognition: Garnered widespread academic citations, reflecting the influence and applicability of his research.
  • Collaboration and Leadership: Actively involved in global collaborations, enhancing the translational impact of his findings.

๐Ÿ“Š ACADEMIC CITATIONS AND METRICS

Dr. Huang’s academic metrics underscore his scholarly contributions:

  • H-Index: Demonstrates significant citation impact in medicinal chemistry and oncology.
  • Published Articles: Over 50 research papers, including breakthroughs in bioorganic and natural medicinal chemistry.
  • Research Grants: Secured funding for multiple national and international projects.

๐Ÿ† LEGACY AND FUTURE CONTRIBUTIONS

As a visionary in drug discovery, Dr. Huang aspires to expand his research impact by:

  • Advancing precision medicine approaches tailored to the tumor microenvironment.
  • Developing next-generation inhibitors targeting stress-response proteins in cancer therapy.
  • Mentoring the next wave of researchers in innovative medicinal chemistry.

๐ŸŒ CONCLUSION

Dr. Shi-liang Huang embodies a blend of academic rigor, research innovation, and educational leadership. His contributions continue to shape the future of medicinal chemistry, with a legacy that inspires collaboration, discovery, and impactful solutions in cancer therapy.

๐Ÿ“Š๐Ÿ”ฌNOTABLE PUBLICATION:
  • A Novel HSF1 Activator Ameliorates Non-Alcoholic Steatohepatitis by Stimulating Mitochondrial Adaptive Oxidation
    • Authors: Rao, Y.; Li, C.; Hu, Y.-T.; Ye, J.-M.; Huang, Z.-S.
    • Journal: British Journal of Pharmacology
    • Year: 2022

 

  • Design, Synthesis, and Evaluation of New Sugar-Substituted Imidazole Derivatives as Selective c-MYC Transcription Repressors Targeting the Promoter G-Quadruplex
    • Authors: Li, M.-L.; Yuan, J.-M.; Yuan, H.; Chen, S.-B.; Huang, Z.-S.
    • Journal: Journal of Medicinal Chemistry
    • Year: 2022

 

  • Discovery of Quinacrine as a Potent Topo II and Hsp90 Dual-Target Inhibitor, Repurposing for Cancer Therapy
    • Authors: Pan, X.; Mao, T.-Y.; Mai, Y.-W.; Huang, Z.-S.; Huang, S.-L.
    • Journal: Molecules
    • Year: 2022

 

  • Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer
    • Authors: Jiang, X.-C.; Tu, F.-H.; Wei, L.-Y.; Chen, S.-B.; Huang, Z.-S.
    • Journal: Journal of Medicinal Chemistry
    • Year: 2022

 

  • Design and Synthesis of Bouchardatine Derivatives as a Novel AMP-Activated Protein Kinase Activator for the Treatment of Colorectal Cancer
    • Authors: Xu, Y.-H.; Hu, Y.-T.; Xu, S.-M.; Chen, S.-B.; Huang, Z.-S.
    • Journal: Journal of Medicinal Chemistry
    • Year: 2023
Assoc. Prof. Dr. Shi-liang Huang | Tumor | Best Researcher Award